Revolutionizing Healthcare with nsPFA™ Technology
"The technology at Pulse Biosciences shows immense potential for treating a variety of health conditions, particularly atrial fibrillation. Its safety and effectiveness in treating over 6,000 patients is truly exciting. We are honored to bring such revolutionary solutions to the public."
Bob Duggan – Founder
Overview
Pulse Biosciences stands at the forefront of biomedical technology as the pioneering inventor and manufacturer of its patented Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. Harnessing the unique potential of nsPFA, the company is committed to addressing high-impact areas in healthcare, with a current focus on cardiology applications.
Pulse Biosciences is investigating a variety of applications for its technology, including immuno‐oncology, dermatology, and veterinary medicine.
Technology
Pioneering Work in Nanosecond Pulsed Field Ablation
The core technology that underpins Pulse Biosciences is the innovative nsPFA. It serves as a powerful tool that can nonthermally clear cells, while sparing adjacent noncellular tissue. This technology delivers nanosecond pulses of electrical energy, with pulse durations ranging from billionths to a millionth of a second.
The nsPFA energy is dispensed through the robust and adaptable nsPFA™ generator platform. This technology has been meticulously designed to connect to various types of applicators, from superficial to surgical to catheter-based therapies, making it a flexible solution for different healthcare applications.
Pulse Biosciences’ nsPFA technology is not merely theoretical; it’s already been used to treat over 6,000 patients safely and effectively outside of Cardiology. This proves the practicality and effectiveness of the technology across a multitude of therapy areas.
The Power and Potential of nsPFA Technology
When the nsPFA energy pulses are applied to targeted tissue, they enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum. This causes a cascade of intracellular disruption that eventually leads to regulated cell death (RCD), a process that occurs when cells in the human body experience stress and cannot restore cellular homeostasis.
Interestingly, the nsPFA technology has shown immense promise in the cardiology field, where it is being explored as a potential treatment for atrial fibrillation. However, the potential applications of this novel technology extend far beyond cardiology, offering hope to patients across a broad spectrum of therapy areas.
Proprietary Technology and Unrivaled Expertise
Pulse Biosciences holds exclusive rights to the nsPFA technology, making it a sole proprietor in this cutting-edge field. The team at Pulse Biosciences consists of top experts in pulsed electric field technologies and possesses wide-ranging engineering expertise across multiple medical device domains.
The company’s commitment to health innovation is clear. By leveraging their unique nsPFA™ technology, they aim to address a variety of applications where optimal solutions remain elusive, thereby fulfilling their mission to improve and extend the lives of patients.
An Expansive Intellectual Property Portfolio
With over 130 issued patents globally owned and licensed, Pulse Biosciences’ intellectual property (IP) portfolio is both deep and broad. This growing patent portfolio not only safeguards their pioneering nsPFA technology but also facilitates the development of a rich pipeline of transformative commercial applications.
The company is resolute in realizing the immense potential of their Nanosecond Pulsed Field Ablation technology. Through their unwavering commitment to innovation and dedication to improving patient lives, Pulse Biosciences is truly revolutionizing the field of healthcare.
"This is an incredibly exciting technology...There’s a whole world, both cosmetic and clinical, including skin cancer that’s going to be looked at continually as we go forward."
Mark S. Nestor – MD, PHD